AstraZeneca Indonesia

Inhalation Center Partnership Program

988C 5529

Author

Yohannes Sinaga

Yohannes Sinaga

School

IPMI International Business School

IPMI International Business School

Professor

Amelia Naim Indrajaya

Amelia Naim Indrajaya

Global Goals

3. Good Health and Well-Being 4. Quality Education 17. Partnerships for the Goals

Keep this story going! Share below!

Summary

Asthma is a major cause of chronic morbidity and mortality throughout the world and there is substantial evidence that the prevalence has increased considerably over the past 20 years, especially in children. Based on the Indonesia Basic Health Research in 2013, the national prevalence of asthma in Indonesia reached 4.5%, which means that of the 220 million population of Indonesia there are 9 million people who suffer from asthma. Although asthma can occur at any age, the incidence of asthma is common in children and young adults. Children who suffer from asthma are often not able to attend class if they are suffering from an asthma attack, which can lead to a decrease in overall school attendance influencing the decline in academic achievement and decreasing the child's social interaction with the environment.

Similar to children, young adults with asthma can suffer the loss of working hours due to the disease, which decreases income. The prevalence of asthma is still rising in developing countries, including Indonesia. The prevalence of asthma in children in Indonesia varies from 2.1% to 32.2% depending on the location. Survey results in some cities in Indonesia (Jakarta, Medan, Palembang, Bandung and Semarang) revealed that the prevalence of asthma among elementary school children (6-12 years old) was 3.7 to 6.4 % and junior high school (13-14 years old) was 8.6 to 13.1%. This indicates that there is a need for an asthma intervention in children, thus highlighting the importance of good asthma management in children. However, diagnosis and management of asthma still needs to be improved both at the hospital and primary health care (Puskesmas) level.

Innovation

The Inhalation Center Partnership Program (ICPP) has been started since 2015 by Astrazeneca Indonesia (AZ) to 126 government hospitals and primary health care services (Puskesmas). The objective of building the inhalation center at government hospital is to improve the skills and capabilities of health care professionals in public hospital and primary health care (puskesmas) especially related to management of asthma, and to provide and set up the nebulizer equipment for managing the asthma patients.

Since the inhalation center was available at hospitals, many patient are able to be diagnosed earlier by doctors."Right now, many patients not only diagnosed earlier, but they could get better treatment and as the result, the quality of life of patients are now improved," Shinta, a Sales Manager of AZ said. "I am so thrilled when I can see children with asthma can now go to school and they can learn as normal kids," Shinta continued to explain.

Inhalation Center Partnership Program

Inspiration

By building and providing the continuous educational activities to patients and health care professionals (doctors), this program has improved proper diagnosis of asthma at 126 asthma centers in Indonesia.

Overall impact

Since this program launched, there are about 150k patients have been diagnosed with proper treatment and follow up.

Business benefit

The respiratory franchise of AstraZeneca Indonesia has doubled its business since the project launched from 4.5 Million USD to 8.5 Million USD

Social and environmental benefit

This project has helped the government hospitals in opening the treatment access and diagnosis to their patients.

Interview

Shinta Caroline, Sales Manager

Photo of interviewee

Business information

AstraZeneca Indonesia

AstraZeneca Indonesia

ID
Business Website: http://www.astrazeneca.com
Year Founded: 1999
Number of Employees: 10000+
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company, which is focusing on 3 therapeutic areas, respiratory, oncology and cardiovascular diseases.